Please ensure Javascript is enabled for purposes of website accessibility
Inicio > Productos Destacados > Línea celular estable

CHO Human CLDN18.2 Stable Cell Line (HX126828)

CHO Human CLDN18.2 Stable Cell Line
CHO Human CLDN18.2 Stable Cell Line
Precio(USD):
Especificación:
  • 1 ml
Número:
Contáctenos
  • Vista general

  • Imágenes

  • Referencias

  • Datasheet

Vista general
Número de catálogoHX126828
Descripción
CHO Human CLDN18.2 Stable Cell Line (HX126828) is a stable cell line expressing CLDN18.2. Engineered for consistent, high-level target expression in research applications.
Highlights
  • ●Stable Expression — Engineered for consistent, high-level target expression.
Número de accesoP56856
AplicacionesFCM
Especie huéspedCHO
EspeciesHuman
Objetivo CLDN18.2
Método de detección Colorimetric
Tipo de muestra Plasma, Serum
Tipo de ensayo Quantitative
Rango 1.56 - 100 ng/mL
Sensibilidad 0.25 ng/mL
Recuperación 80-120%
Propiedades Growth Properties: Adherent; Selection Marker: Puromycin (1 μg/mL)
Envío 2-8 ℃
Estabilidad y almacenamiento Frozen in liquid nitrogen.
Especificaciones 1 vial contains at least 2×10^6 cells in 1 mL Freeze Medium
Fondo

Claudin-18 (CLDN18.2) is a ~27 kDa protein. Involved in alveolar fluid homeostasis via regulation of alveolar epithelial tight junction composition and therefore ion transport and solute permeability, potentially via downstream regulation of the actin cytoskeleton organization and beta-2-adrenergic signaling. Required for lung alveolarization and maintenance of the paracellular alveolar epithelial barrier. Acts to maintain epithelial progenitor cell proliferation and organ size, via regulation of YAP1 localization away from the nucleus and thereby restriction of YAP1 target gene transcription. Acts as a negative regulator of RANKL-induced osteoclast differentiation, potentially via relocation of TJP2/ZO-2 away from the nucleus, subsequently involved in bone resorption in response to calcium deficiency. Mediates the osteoprotective effects of estrogen, potentially via acting downstream of estrogen signaling independently of RANKL signaling pathways. CLDN18.2 is the therapeutic target of zolbetuximab (Vyloy).

Nota For research use only. This stable cell line expresses GFP as a reporter marker. GFP is expressed independently of the target protein and is not fused to the target protein.
Imágenes
  • CHO Human CLDN18.2 Stable Cell Line

    Flow cytometry

    Untransfected cells (blue Histogram) and Transfected cells (Yellow Histogram) were stained with an anti-human CLDN18.2 monoclonal antibody at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer.

Referencias
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recomendación

Contáctenos para cotizaciones personalizadas, solicitudes en masa y cualquier otro problema.

Correo: [email protected]

Lista de distribuidores